Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- patients admitted at the emergency department with a diagnosis of severe sepsis or septic shock in whom amikacin is indicatied~Exclusion Criteria:~* \< 18 years~* pregnancy~* burns~* amikacin treatment in the previous 2 weeks~* known allergy to aminoglycosides~* Do Not Reanimate Code ≥ 2~* Hospitalized patients with a prolonged deep venous or arterial catheder~* Continuous renal replacement, intermittent hemodialysis and death within the time of start of amikacin replacement and 1 hour later

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amikacin standard dose (Type: ACTIVE_COMPARATOR): amikacin in a single standard dose
- amikacin dose for critical care patients (Type: ACTIVE_COMPARATOR): amikacin in a single dose for critical care patients

Based on this trial design, predict the completion outcome and termination type (if applicable).